<SEC-DOCUMENT>0001818382-24-000034.txt : 20240322
<SEC-HEADER>0001818382-24-000034.hdr.sgml : 20240322
<ACCEPTANCE-DATETIME>20240322070601
ACCESSION NUMBER:		0001818382-24-000034
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240322
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240322
DATE AS OF CHANGE:		20240322

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Humacyte, Inc.
		CENTRAL INDEX KEY:			0001818382
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851763759
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39532
		FILM NUMBER:		24773073

	BUSINESS ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		919-313-9633

	MAIL ADDRESS:	
		STREET 1:		2525 EAST NORTH CAROLINA HIGHWAY 54
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Alpha Healthcare Acquisition Corp.
		DATE OF NAME CHANGE:	20200716
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>huma-20240322.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:44a341cd-3a0f-4ac6-aa5d-24b7e3c4115c,g:c24c045b-5317-4b7a-a24b-175ef1743377,d:f508cad80efc4f9eb28ef21475ab39bf-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>huma-20240322</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0001818382</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-27">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="huma-20240322.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818382</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-22</xbrli:startDate><xbrli:endDate>2024-03-22</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if508cad80efc4f9eb28ef21475ab39bf_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 22, 2024</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-4">Humacyte, Inc.</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-5">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39532</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-7">85-1763759</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.810%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-8">2525 East North Carolina Highway 54</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Durham,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">NC</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">27713</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">919</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">313-9633</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.628%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-17">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to 12(b) of the Act:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which<br/>registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-19">HUMA</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-21">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-22">HUMAW</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="if508cad80efc4f9eb28ef21475ab39bf_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02. Results of Operations and Financial Condition</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 22, 2024, Humacyte, Inc. issued a press release regarding its financial results for its fiscal fourth quarter and full year ended December 31, 2023. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained herein, including the exhibit attached hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></div><div id="if508cad80efc4f9eb28ef21475ab39bf_10"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="huma-20240322xexx991.htm">Press release, dated March 22, 2024.</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="if508cad80efc4f9eb28ef21475ab39bf_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMACYTE, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March 22, 2024</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/ Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dale A. Sander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Chief Corporate Development Officer and Treasurer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>huma-20240322xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i805bb5ef3bf44b508e27612c5bf4737d_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:10pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:316px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">-Biologics License Application (BLA) for HAV&#8482; Accepted by FDA on February 8, 2024-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">-BLA Granted Priority Review for Vascular Trauma Indication&#59; PDUFA date set for August 10, 2024-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">-Raised approximately $43.1 million in net proceeds from public offering of common stock-</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-Conference call and live webcast at 8&#58;00 a.m. ET today-</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DURHAM, N.C., March 22, 2024</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tissue at commercial scale, today announced financial results for the fourth quarter and year ended December 31</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2023 and highlighted recent corporate accomplishments in </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advancing the investigational Human Acellular Vessel (HAV) closer to planned U.S. market launch.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;During 2023, we accomplished major goals across all of our clinical programs. In December 2023, we submitted our Biologics License Application (BLA) to the Food and Drug Administration (FDA) seeking approval of the HAV in the vascular trauma indication,&#8221; said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. &#8220;The FDA&#8217;s acceptance of our filing in February 2024 brings us another major step closer to our goal of providing an innovative regenerative medicine product for patients suffering traumatic vascular injury. We believe the FDA&#8217;s decision to grant Priority Review reflects their recognition that many patients with severe injuries are underserved by the current standard of care.  We look forward to working with the agency toward their Prescription Drug User Fee Act (PDUFA) date of August 10, 2024.&#8221;</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;During the year we were also pleased with the progress made in our broader HAV pipeline, including completion of enrollment of our V007 Phase 3 trial of the HAV for use in AV access for hemodialysis, presentation and publication of clinical trial results in severe peripheral artery disease (PAD), and publication of preclinical results for our small caliber HAV in a juvenile heart disease preclinical model. The coming year will be exciting, and we thank the medical professionals, patients, researchers and our employees for their contributions to the continued advancement of the HAV,&#8221; concluded Dr. Niklason.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter 2023 and Recent Corporate Highlights</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical and Regulatory Updates</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:13.8pt">Biologics License Application for HAV Granted Priority Review by U.S. FDA for the Vascular Trauma Indication </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; In February 2024, the Company announced that the FDA had accepted and granted Priority Review to its BLA seeking approval of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated, and when autologous vein use is not feasible. The BLA submission is supported by positive results from the V005 Phase 2&#47;3 clinical trial, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. The HAV was observed to have higher rates of patency (blood flow), and lower rates of amputation and infection, as compared to historic synthetic graft benchmarks in both the V005 Phase 2&#47;3 clinical trial and the Ukraine humanitarian program.</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PDUFA date, the FDA action date for their regulatory decision regarding the BLA, is August 10, 2024. The Priority Review designation is a mechanism reserved by FDA for products that, if approved, would significantly improve the treatment, diagnosis, or prevention of serious conditions. Priority Review applications have a six-month review time instead of ten months for a standard review. The Priority Review aligns with the Regenerative Medicine Advanced Therapy (RMAT) designation granted by the FDA in May 2023 for urgent arterial repair following extremity vascular trauma. The Priority Review is also consistent with the priority designation given by the Secretary of Defense under Public Law 115-92, which was enacted to expedite the FDA&#8217;s review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel.</font></div><div style="margin-top:12pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentations and Publications</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Presentations at a Major Vascular Surgery Symposium</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Two presentations were made at the VEITH Symposium, a major vascular surgery meeting, held in New York City on November 15-18, 2023. These include an expanded presentation of positive results of the V005 vascular trauma trial, with the HAV observed to have higher rates of patency and lower rates of amputation and infection as compared to historic synthetic graft benchmarks.</font></div><div style="margin-top:12pt;padding-left:36pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results of the V005 trial were presented by Charles J. Fox, MD, FACS, Director of Vascular Surgery at the University of Maryland Capital Region, a clinical investigator in the V005 trial, in a podium presentation titled &#8220;Phase 2&#47;3 Study for the Evaluation of Safety and Efficacy of HAV for Vascular Reconstruction in Patients with Limb or Life-Threatening Vascular Trauma.&#8221; Results from V005 and the Ukraine humanitarian program, with statistical comparison to historic benchmarks, were presented at a symposium titled &#8220;Vascular Trauma Repair Clinical Study Results with Humacyte Human Acellular Vessel (V005 &#38; V017 Data)&#8221; by Dr. Moore, Dr. Fox, and Laura Niklason, MD, PhD, Chief Executive Officer of Humacyte.</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Publication of Preclinical Results in Juvenile Heart Disease Study</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, a publication in the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of Thoracic and Cardiovascular Surgery</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> described a preclinical study showing the potential for the investigational small-diameter HAV to treat tetralogy of Fallot, a heart condition that affects one in every 2,000 babies born each year in the United States. In the preclinical study, researchers from Nationwide Children's Hospital (Columbus, OH) and Humacyte implanted 3.5mm diameter HAVs into a juvenile animal model of pediatric heart disease. The 3.5mm HAVs remained patent for up to six months, and evidence of HAV repopulation by host cells was observed, similar to what has been observed in human patients. In connection with the study, Humacyte produced 3.5mm vessels using the same manufacturing platform used to produce Humacyte&#8217;s 6mm HAVs that are in current clinical use.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HAV is an investigational product and has not been approved for sale by the FDA or any other regulatory agencies.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fourth Quarter and Full Year 2023 Financial Highlights</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reported cash and cash equivalents of </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$80.4 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2023. In addition, Humacyte completed two transactions in early 2024 which added to its cash balance. On March 5, 2024, the Company closed an underwritten public offering of its common stock and raised net proceeds of approximately $43.1 million. Furthermore, on March 11, 2024, the Company received $20 million in proceeds from an additional draw under its previously disclosed funding arrangement with Oberland Capital Management. Total net cash used was </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$69.0 million for the year ended </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$67.7 million for the year ended </font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022. Humacyte believes that its cash and cash equivalents, including net proceeds from the March offering and additional draw under the Oberland funding arrangement, will be adequate to finance operations for at least 12 months from the date of this financial report, well past the currently anticipated timelines for FDA approval of commercialization of the HAV in the vascular trauma indication.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There was </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no revenue</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for either the fourth quarter of 2023 or the fourth quarter of 2022, and there was </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenue for the year ended December&#160;31, 2023. Revenue was </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.6 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022, and was related to a grant supporting the development of the HAV that was completed during 2022.</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Research and development expenses were </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.2 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, and were </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$76.6 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$63.3 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. The 2023 increases resulted primarily from increased personnel, external services expenses and materials expenses to support expanded research and development initiatives and our clinical trials, including the </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">completion of our V005 Phase 2&#47;3 and V017 Ukraine Humanitarian trials for the use of the HAV in extremity vascular trauma, our BLA filing in December 2023, and expansion of clinical development of the HAV for use in AV access for hemodialysis. </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.0 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.8 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, and were </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$23.5 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22.9 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. The slight net increases in 2023 resulted primarily from increased personnel costs, primarily driven by preparation for the planned commercial launch of the HAV in the vascular trauma indication.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other net income (expense) was net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income of </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2023, compared to net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.1 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, and was net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$10.7 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023, compared to net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income of</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$72.6 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. The reduction in other net </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2023, and the increase in other net expense for the year December&#160;31, 2023, resulted primarily from the non-cash remeasurement of the contingent earnout liability associated with the August 2021 merger with Alpha Healthcare Acquisition Corp.</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss was </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$25.1 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.7 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the fourth quarter of 2022, and net loss was </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.8 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023, compared to </font><font style="color:#231f20;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million</font><font style="color:#0a0a0a;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2022. The 2023 increases in net loss resulted from the non-cash remeasurement of the contingent earnout liability, and operating expense increases, described above.</font></div><div style="margin-bottom:3pt;margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Details</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.134%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Humacyte Fourth Quarter and Year End 2023 Financial Results and Corporate Update</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Friday, March 22, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#58;00 a.m. ET</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call Details&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Toll-Free&#58; 1-877-704-4453<br>International&#58;  1-201-389-0920<br>Conference ID #&#58;  13744046</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Call me</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Feature (avoid waiting for operator)&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Click Here</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Webcast&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#026dce;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Webcast Link - Click Here</font></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company&#8217;s website for at least 30 days.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Humacyte</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humacyte, Inc. (Nasdaq&#58; HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte&#8217;s initial opportunity, a portfolio of HAVs, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, AV access for hemodialysis, and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte&#8217;s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA&#8217;s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte&#8217;s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received an RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.</font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words&#58; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing&#8221; or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines&#59; our plans and ability to obtain marketing approval from the FDA and other regulatory authorities for the HAV and other product candidates&#59; the outcome of the FDA&#8217;s review of our BLA seeking approval of the HAV in the vascular trauma indication&#59; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials, including for our V007 Phase 3 clinical trial&#59; the characteristics and performance of the HAV&#59; our ability to manufacture HAVs and other product candidates in sufficient quantities to satisfy our clinical trial and commercial needs&#59; our plans and ability to commercialize the HAV and other product candidates, if approved by regulatory authorities&#59; and our anticipated cash runway. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and&#47;or competitive factors, and other risks and uncertainties, including those described under the header &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2022 and in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte&#8217;s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Investor Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Joyce Allaire</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeSci Advisors LLC</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-617-435-6602</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">jallaire&#64;lifesciadvisors.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">investors&#64;humacyte.com</font></div><div><font><br></font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte Media Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rich Luchette</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Precision Strategies</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+1-202-845-3924</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">rich&#64;precisionstrategies.com</font></div><div style="margin-top:2pt"><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">media&#64;humacyte.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div><font><br></font></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><div id="i805bb5ef3bf44b508e27612c5bf4737d_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.35pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands except for share and per share amounts)</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended<br>December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended</font></div><div style="text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant revenue</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,180&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,550&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,260&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,002&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,833&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,497&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,883&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,182&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,790&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,047&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,143&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(26,182)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(20,790)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(100,047)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(84,578)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,685&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,118&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,023)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,767&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (net)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,154)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net </font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,076&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,070&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,729)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,613&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss and comprehensive loss</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,106)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,720)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(110,776)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11,965)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.04)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.07)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1.85pt;padding-left:9pt;text-indent:-9pt"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding, basic and diluted</font></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,607,631&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,162,219&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,420,238&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,051,366&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><div id="i805bb5ef3bf44b508e27612c5bf4737d_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humacyte, Inc.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><font style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of December&#160;31,</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,448&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,772&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,830&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,278&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,208&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,791&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,039&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,313&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </font></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,490&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,340&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,108&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,613&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,306&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, current portion </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,571&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,443&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,580&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,893&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease obligation, net of current portion </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,853&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVB loan payable, net of current portion</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,336&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </font></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">114,677</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">87,374</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock and additional paid-in capital </font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550,860&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,466&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,314)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426,538)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,546&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,928&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128,223</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">204,302</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>huma-20240322.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:44a341cd-3a0f-4ac6-aa5d-24b7e3c4115c,g:c24c045b-5317-4b7a-a24b-175ef1743377-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:huma="http://www.humacyte.com/20240322" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humacyte.com/20240322">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240322_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240322_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="huma-20240322_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.humacyte.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>huma-20240322_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:44a341cd-3a0f-4ac6-aa5d-24b7e3c4115c,g:c24c045b-5317-4b7a-a24b-175ef1743377-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240322.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2333044b-164f-4396-ae88-d548f8ab1c49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:to="loc_us-gaap_ClassOfStockDomain_2333044b-164f-4396-ae88-d548f8ab1c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:to="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8d9fc10e-7fea-4461-b364-ca71b8d6529b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:to="loc_us-gaap_CommonStockMember_8d9fc10e-7fea-4461-b364-ca71b8d6529b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8ac56e26-7496-46ae-973d-da8a9586740d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:to="loc_us-gaap_WarrantMember_8ac56e26-7496-46ae-973d-da8a9586740d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_093bb847-ff56-4847-8ff2-04abbcb846c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_DocumentType_093bb847-ff56-4847-8ff2-04abbcb846c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cfe5e0a9-5499-498d-a830-cf6889bc69bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_DocumentPeriodEndDate_cfe5e0a9-5499-498d-a830-cf6889bc69bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9a362e34-f729-4556-a522-9b68ec1cc9b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityRegistrantName_9a362e34-f729-4556-a522-9b68ec1cc9b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_92171844-70e7-495f-9d08-7eeabb193ce6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_92171844-70e7-495f-9d08-7eeabb193ce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5987d308-5079-4e5c-9b6b-7b94e8844c04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityFileNumber_5987d308-5079-4e5c-9b6b-7b94e8844c04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_abeeb0e2-6656-41fe-b562-454e5a8d7732" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityTaxIdentificationNumber_abeeb0e2-6656-41fe-b562-454e5a8d7732" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d281b1b3-8e35-44d4-8fb5-7e01effb1e8e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressAddressLine1_d281b1b3-8e35-44d4-8fb5-7e01effb1e8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_78986b14-d067-4617-a73b-49f89e2f98a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressCityOrTown_78986b14-d067-4617-a73b-49f89e2f98a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e89bef7d-48b2-4beb-ae71-9054837364e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressStateOrProvince_e89bef7d-48b2-4beb-ae71-9054837364e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1144e86c-3e46-4c64-ab67-5de749f5e47c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressPostalZipCode_1144e86c-3e46-4c64-ab67-5de749f5e47c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6f6d6238-7644-46de-9f76-a586de77b2cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_CityAreaCode_6f6d6238-7644-46de-9f76-a586de77b2cc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a247c387-c4d5-4cc6-8bbc-76f186bb881d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_LocalPhoneNumber_a247c387-c4d5-4cc6-8bbc-76f186bb881d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_52a76538-7c8e-4c4e-b165-cce37fddcfb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_WrittenCommunications_52a76538-7c8e-4c4e-b165-cce37fddcfb1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b091ba5f-a214-4471-b0e7-ae461efe558e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_SolicitingMaterial_b091ba5f-a214-4471-b0e7-ae461efe558e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a63b8414-aa5f-4626-9ab8-ddf0fb3a6b9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_PreCommencementTenderOffer_a63b8414-aa5f-4626-9ab8-ddf0fb3a6b9b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_237a6b49-9323-4faf-aac8-50736ea3500f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_237a6b49-9323-4faf-aac8-50736ea3500f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b13c218d-67c3-4141-ae93-5938c4d24eb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_Security12bTitle_b13c218d-67c3-4141-ae93-5938c4d24eb1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9724144-6df0-41e7-b096-5c525345733d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_TradingSymbol_c9724144-6df0-41e7-b096-5c525345733d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_96d78167-2b20-4519-90ed-c28a571ede83" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_SecurityExchangeName_96d78167-2b20-4519-90ed-c28a571ede83" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_52e2707e-f7b0-45e1-be68-5905d221e744" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityEmergingGrowthCompany_52e2707e-f7b0-45e1-be68-5905d221e744" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6019e0f2-e311-4e44-863b-9de5d4146101" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityExTransitionPeriod_6019e0f2-e311-4e44-863b-9de5d4146101" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dbf44b90-6560-405f-bffa-e9f24cda868c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityCentralIndexKey_dbf44b90-6560-405f-bffa-e9f24cda868c" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27b00802-6786-45c8-bad3-777699139e5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_AmendmentFlag_27b00802-6786-45c8-bad3-777699139e5e" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>huma-20240322_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:44a341cd-3a0f-4ac6-aa5d-24b7e3c4115c,g:c24c045b-5317-4b7a-a24b-175ef1743377-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityInformationLineItems_287edb8f-db08-4594-a934-3195818214b8_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f286523e-469f-4dce-8135-b4489d7bd2a3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_eda3a1be-8475-4a2f-b6d2-edb219c3ff1c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, par value $0.0001 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_d374cf8b-d903-4655-999a-d0de34c50667_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_7f2a1181-0205-4d30-b7b4-8b9bd02551a2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_2f618224-a4bb-4f18-88a1-0ad7616baaef_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ebba5b2c-e06b-4050-bcf6-2b1c98531ee2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ab152706-c349-4624-85d8-e7334c622c32_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d38d88cd-9bc5-40d8-8b2b-227736cf14a4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7fa7682c-b35a-4527-a4a3-77e5e05407cc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c8b395f0-c6f8-479f-9c4c-b97d867200c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_300e1e23-09e8-4dc0-800b-30c2856fd7db_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_17d16653-0749-4500-91fe-d8a434ab9251_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7c37d65f-41f9-4221-8a71-785bd35b0e5f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6b89d2cf-fe1a-4520-ad4f-c312e6e57f1d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4a65d2a8-fe53-4e7a-af68-ab915f853db7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2c639140-2114-49d2-80c5-196d1c322071_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_533e0cf8-a17e-4762-aa9e-7554698923aa_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7cbc73a3-e397-4c70-b5b7-1fe66f901799_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7cc123f1-24d8-46ed-8d90-fb64045c3d41_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8bc9b2ae-39b8-4591-b8a5-c182f745cd60_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c59731a8-1562-4d4a-9d9e-d639a6952abb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_99338e92-3479-408c-85cb-952c0b74891c_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5238b6fc-371c-4476-bbe2-49c7fe775083_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2e8270d9-11f6-4c40-af9d-ab85edefb99c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_83d0f32c-6827-4d71-b765-f45446486e92_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f03343d1-647e-4021-8108-2a38e1d6c384_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_197c6d1c-e2bd-4152-b118-86560405ce37_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c02d0a46-4307-4fc2-92b0-62c5055a5e78_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>huma-20240322_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:44a341cd-3a0f-4ac6-aa5d-24b7e3c4115c,g:c24c045b-5317-4b7a-a24b-175ef1743377-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humacyte.com/role/CoverPage" xlink:type="simple" xlink:href="huma-20240322.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.humacyte.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_485824f2-4734-47ca-ab64-5c7b93eb51b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_485824f2-4734-47ca-ab64-5c7b93eb51b2" xlink:to="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2333044b-164f-4396-ae88-d548f8ab1c49" xlink:to="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8d9fc10e-7fea-4461-b364-ca71b8d6529b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:to="loc_us-gaap_CommonStockMember_8d9fc10e-7fea-4461-b364-ca71b8d6529b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8ac56e26-7496-46ae-973d-da8a9586740d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_104507e6-2109-488a-b212-8e51312aa94d" xlink:to="loc_us-gaap_WarrantMember_8ac56e26-7496-46ae-973d-da8a9586740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_bc927fdb-0504-4efa-8c1a-e58c010dcd2e" xlink:to="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_093bb847-ff56-4847-8ff2-04abbcb846c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_DocumentType_093bb847-ff56-4847-8ff2-04abbcb846c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cfe5e0a9-5499-498d-a830-cf6889bc69bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_DocumentPeriodEndDate_cfe5e0a9-5499-498d-a830-cf6889bc69bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9a362e34-f729-4556-a522-9b68ec1cc9b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityRegistrantName_9a362e34-f729-4556-a522-9b68ec1cc9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_92171844-70e7-495f-9d08-7eeabb193ce6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_92171844-70e7-495f-9d08-7eeabb193ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_5987d308-5079-4e5c-9b6b-7b94e8844c04" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityFileNumber_5987d308-5079-4e5c-9b6b-7b94e8844c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_abeeb0e2-6656-41fe-b562-454e5a8d7732" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityTaxIdentificationNumber_abeeb0e2-6656-41fe-b562-454e5a8d7732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d281b1b3-8e35-44d4-8fb5-7e01effb1e8e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressAddressLine1_d281b1b3-8e35-44d4-8fb5-7e01effb1e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_78986b14-d067-4617-a73b-49f89e2f98a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressCityOrTown_78986b14-d067-4617-a73b-49f89e2f98a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e89bef7d-48b2-4beb-ae71-9054837364e8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressStateOrProvince_e89bef7d-48b2-4beb-ae71-9054837364e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_1144e86c-3e46-4c64-ab67-5de749f5e47c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityAddressPostalZipCode_1144e86c-3e46-4c64-ab67-5de749f5e47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_6f6d6238-7644-46de-9f76-a586de77b2cc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_CityAreaCode_6f6d6238-7644-46de-9f76-a586de77b2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a247c387-c4d5-4cc6-8bbc-76f186bb881d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_LocalPhoneNumber_a247c387-c4d5-4cc6-8bbc-76f186bb881d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_52a76538-7c8e-4c4e-b165-cce37fddcfb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_WrittenCommunications_52a76538-7c8e-4c4e-b165-cce37fddcfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b091ba5f-a214-4471-b0e7-ae461efe558e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_SolicitingMaterial_b091ba5f-a214-4471-b0e7-ae461efe558e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_a63b8414-aa5f-4626-9ab8-ddf0fb3a6b9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_PreCommencementTenderOffer_a63b8414-aa5f-4626-9ab8-ddf0fb3a6b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_237a6b49-9323-4faf-aac8-50736ea3500f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_237a6b49-9323-4faf-aac8-50736ea3500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b13c218d-67c3-4141-ae93-5938c4d24eb1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_Security12bTitle_b13c218d-67c3-4141-ae93-5938c4d24eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c9724144-6df0-41e7-b096-5c525345733d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_TradingSymbol_c9724144-6df0-41e7-b096-5c525345733d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_96d78167-2b20-4519-90ed-c28a571ede83" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_SecurityExchangeName_96d78167-2b20-4519-90ed-c28a571ede83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_52e2707e-f7b0-45e1-be68-5905d221e744" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityEmergingGrowthCompany_52e2707e-f7b0-45e1-be68-5905d221e744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6019e0f2-e311-4e44-863b-9de5d4146101" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityExTransitionPeriod_6019e0f2-e311-4e44-863b-9de5d4146101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_dbf44b90-6560-405f-bffa-e9f24cda868c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_EntityCentralIndexKey_dbf44b90-6560-405f-bffa-e9f24cda868c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_27b00802-6786-45c8-bad3-777699139e5e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_cf5cb249-32ce-44d1-b53e-13798ad6a041" xlink:to="loc_dei_AmendmentFlag_27b00802-6786-45c8-bad3-777699139e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
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M;5:?]5";A.'$.M7Q-:JCJU1'5JH.KT#_J[A\3%-P4X_7 @        !) L+
MAJH"?4JP-MQ;&>&M#O-Z6!BV6!.&0\M4 >XJ_Z6J8QO5-V)T>%T
MD!@@#,R0UU)IY[67?#47?307=JMI"L.QU;@P'%BL\ENH.KY.77@+M $
M  "0+B ,#"A(U<7L547MU7 E#/L6J/:ZJ2X<U.BT,+<!        D"(@#+30
M**G48'7,?DWT/@TF#.%LA6'_HOO"X.NJ/+!"U5 -S@        !(#A"&IE'6
M4?%'5;$'-/P)@\]\I?<\>641. ,        @+4 8FD!1IX\_(HOSYUT8=LU5
M[IR#G $64 (        D! B#-9 M7#E2'Q\@%T88O&<K/6?+%?5PG@$
M  "0"B ,%J'TAN03-5<"ZN(#!#K#@(1AYRRE]UPYWA4         $ D0!HND
MGZM).%@MO##LF*$\OEF)]P8         Q "$P3Q%UV4)!RNL"$,DG\*P?88\
M)PWV9P        #$!X3!#%J5/O%(*4_"<-"*,,RY+PR>TY4[IL&%20
M (#X@#"8X69$V=5#)2R$(9@[8=@V37DE1(OW#         "$!80!1UFO33I4
M( 5AV#8#3C(         (@/"@)-QOB3Q<"%=8=C%HS!LG:+,3H-M&0
M   Q 6%X"$I/)1\K^$L8RL41AID/A&'W?!7>10         0$!"&ARBX5IEX
M.,]68=C,F3!LF0I7)0$       !B L+P$.FG<YL0!C^6PG!T%2MAF*PLRH2K
MD@        #1 &%XB)3C62R$(6PGC\(0N$.-]Q(         A *$X0&R2D72
M$5(8:GD4AH46A6'[7\*P!39D         ,0#A.$!1=<JN!2&C=P(P]8I( P
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M,'@1PK 9-GL&        Q$,X8= 4>=$1!IVB!&\I%.GG<B4H#+ / P
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M%@8CE*9"4WY6G>^CRM^CK8Y#_XW?0R3DU2IVPA"Z@WMAV#9%KE;@/00
M    (1%'&*1,RLD"0A@:1!&&_<M %P        "1 6' *;]3SYDP;& O#%NG
MR^NJ8+HS        (#(@#&9(.4Y#&'S9"L,R6L)P>(,*[Q8         " X(
M@QFJ\Q0)AXO8",,VCH1AIEP'NR\         $@"$P3PWSE=@PA#GSZ,P^+H^
M$ ;/6?);"3J\0P         @!B ,YM%KJ:1CW C#B;7,A"%HEQKO#0
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M"$.HKSHK18]7Y)GZ&NK(%M7,7@U3>\JF_""C(PRF3.W9$+A;K=7 9P$
M '<Y?S'I.Z?YC[W>I]5K=_.40[]?QZ\M+JW"[P=(CSO9Q8M6'_BT^S3C:V?,
MXVT<._><N7#U_NQ<\_+ 4!AT]?IKC:]$LB@,FH17#/71>//F!1I#%]_4I85J
M+_DU(0PGURLN'=3<BM?550@][-;K#>&'U7.<&F;\+)_VHXR%,!@SRU%^M5G/
MM<C-+[L0G1J7>%,F4^+_9I\4%%6@1Q23D*%2-><7#@   !"8)>O\3:K0.$@;
MHN*NX_<&)$-I><WP21O(%PXS!W2?BDK\0B&&PE"^B5 %4AA>N"L,5U_1WOH5
M;]Y\4390U45448;NSA7=[7C=[3C=K5A=7KJN-$LG%V\R0'VUP6.Z<G9O^<Q>
M<AN%P1B?9<KF=ZIAY[YS[W8>;?I3>=JA_R^C5]V\4X#?SW[P]@MY[XNQC?_^
MT2/*SC/_FP$     T&?MUF./MNY-#C1-*:^HQ=L $B L,N6?'88T?J5>:#^H
M<\^9WSFY_K?'M.?;#6S\3Z]]Z!P1=:UQ<V;"0&7W)U3!HC"HXM^D]+!:J&CD
MW-#].:!A3E^Y21BFVRP,*.[#&V1US<09=#K]H-&KR \[%/27$Q@<AS>P!YR&
MNY,/!^5)!\=SX8GXO0$   " -O4-BF?>[$=^Q33.=T[S\6: V!P-O/R$@Y/Q
M!7J\C>.8&5LB8](:WP&-B**OW!@^:0/Z5]/=#I^*,MV!F3#H;W]%J()%8= D
MM*8T97@)0!"2([7S^\GG.LHY%P:4^;_(FH<SC)NUE?RD,P4YPXU;^7@;:?/[
ME(WD VF<K)P2O T     T&/T],WD-PN9NGHYWA(0CZC8=),M_.N;"6DW<O%[
M-"(I-;/#E^.,=W[ZC?Y7DFX9;P=A:(;D7->Y]I?S)PPH"X;([?W:I-3K.>1G
M'):>@]WP9A(F,Z?8],. I7S9:P:L90$   "PH]UG8\AO%C(E9=5X2T D:FH;
M6G<<9GQ=_M-C6GW#W9T/0B.3?0/"&B<BZII6>W_USJKJ^D^[3S8V>?M3%Z7R
M[N5"S(2!RAU*J()%85!=><M ";UR*%!50OTY4&X4AGE.? D#BL=,^YX</'G>
M3O(SCDQ1227>4JJ,F+R>[#^9XA)8Q0(   !@0]M.+N37"AE8+DDZ+%T78'Q1
M'/[].S(!=$MI60WYDJ&T^WSTY?@;QE9%)56O?.!LO'W1F@,&QL)0N9M0!8O"
MH,L<C[<'>$:KH5:.4C0A##VX$0:4L,-V/$?EZ]ZSR;\6,F?.7\%;2I5.W::0
M_2=S+3T;;PD     - !AL"]J:AN>??/^;&:_(Q'&&PN+*\F7S)A_=AABFK..
M[F^\\:7W!BF5:F;"8*"T^K1W"%MX( SZQ.=,PF"0I^#- 9X)]%(M^$4NF#!,
M_5ENOY,9WOF4UJ?>@6,7\992I?WGM,X47TVY@[<$     !J ,-@7ATY>,KXB
M[WTQSG1C8V$P[MIV-C2AS<?W+UN:[+K#>#>=3O_F)R.,-YX(BF4H#$@9:D[H
M4YYH4ACT>;/QEBT,M=P@KZ/DM91&J"MW:LJIA8/E0@H#RK9Y0CT\KFE^PO#.
M9[0>$0@#    P X0!OO"M!3*C(7>IAL;"X/IQO6>)XRW?--GKNG&:6[>QALG
MSO-D+ QW*5M'.,-#PJ#+_)6B[/AB%5LHN:._>E9[WONAC=M.;U/%G=(4WM+S
M-]\4%=XR6VE>&/KP* R3N]775O'UH'@%A $     & '"8%_\WS<3C*_(V= $
MTXUFA6'\7^M&#G!98;KQ^-D8XXU?_#B3E3 @ZL_KK_\?*0S:% =]J4?+G.M<
M?%L?X:,^M_7>3L\>#PG#\36JHZM41U:J3F]1YZ7Q\N14EU&+ALCI"\.D;MP(
M \K>E79YD@&$ 0     8 <)@7YA64[V=562ZL;$P+%[KC_+KA'6F>_HW&O;$
M)]XRWO@V&C*9;F4!51=,%<VA<@93=WZF\B<9J@X8] WXG5H&UT*T(=O5P=N:
M$(9#RU4'EZFBCF@X/].P?Y5*+&&8[6B7+SH( P     P H3!OC"](I:$ <ND
M>?<G,!C)RBDQWFZK, !&H@YH0G>H26$(M" , 4M509XJ#IU!JS$L^55A$@8W
M884!)?^.'N^3Y %A      !&@##8%Z8=&*Y=?[! 8F-A0";PS!OWM^X>/VMK
MHZ9WB8Q),_[3!U^/!6&PE:NG-6$[U4R%X< 2U7E?SJ9Y5!3JQ16&0QXJO$^2
M!X0!     !@!PF!??.LXS_B*[#YPWG0C-H?!:U^P\?]_]0-GXQYM)CSW!!G_
MJ;?S$A &FRB\K@OW5K,3AOV+5=G7N/EA_LQNC;C"L&K\W8T#[0L0!@    !@
M! B#?;%BTV'C*S+ 9:7I1DP8ZNKE_^@PU/B?J[<<?=#88!C@LL)X^Z(U!T 8
M;"+"5VF+,/@MY.:'^95C%.(*@]L0.=XGR0/"      ", &&P+^(3;QI?D6?;
M#C1N\VP@A &!/,'XGZ]]^. D0VEY]>-M'(VW)Z=E@3"PIR!-?V&7VD9AR$RR
M==$DG=:PU%ED89C^$PB#^( P     +P"PF!WF%96'3OS_A0%4AC**VM-,QG6
M;#UFO''$Y/M[.'SQ\TSTGR ,[(GR5]LN# <6V7HQCT9%T1>&:?P(P^1N][75
MC@!A      !&@##8'4%A"<87Y?$VCL?/Q*!;2LMJWO[4Q1C3W=PW!!AO^;SG
M#*U6%W \TO1J7KB<:@!AL(6+OBK6PN#_ES#L6V#K54DJQ7UA6"R>,*#@W9(\
M( P     P @0!GMDR-@UQM?EV;8#3P;%XO],@&S!=#&2RS0/XXT@#.R)V&5>
M&(*$%0:E7'QAF-+#_K9B &$      $: ,-@C]0WR?W>=;'QID E,G.=IFL^
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M0O)MO+HY0!B80E,8BDNK\):29-7FHV3G&>79M@-=IGJ</!?;(*-U249-;4/
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M0L-CK_?A::J5">D* Z655<;-*;\PLDEAR M959UQ 6_/A/1SZ:R%(<);K=.
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M_ D]J)G56]Y8&*;8)@PH*\?Q,@=?2$ 86-"M/ZUQV/?]7?&6DN3 L0MDY\F
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MC5>W 'IOA$8FCYFQA>EB3606KMZ/5^>3N\)@T)3H4_Y." #3W!4&JF05?@1
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MSK-M!\Y:["-7J/ ^B0<( ]!" 6$0A;5;CS_;5KC+0Q]OXS37?4]=O1SOQSU
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M7TK!NP4 O"&:,,@3^S$7AHE-"D,.(0S*JG+\V%P0?]#\I&?.A:&RF,?-J@$
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MD5_(RY75 , (T82!TFMDL=];%H:!G B#HJH,/S!W7#FFY548/*?)=?!K @
M  #8(0J%ZN2YV#]7[$/C_N?;#225@#2$?W>=/'C,JE6;CUZXG*I4JO&* " >
MH@D#0G%S+J_"D!UR@-+K\*-R1WTE%;%+912&<+;"L'^116$XL@D^+     "@
M.5!7+\_)+[V371P:F>P;$&;,Z9 K%Z)3TV_F%954X@T 0$J(*0RZAMNU#PM#
M#6MA"%E%"D-#<0Y^2*Z).WC_# /GPK!SNERMP \'          (CIC @%!EN
M30I#^861+(0A]](12L?CZ04CBCHJPD?)N3#LF"U/"H6KD0        #Q$5D8
M*$UU;9PC*V&89UT8-+(Z_&#\D)VHY4H8?/X2AA-P,1(        @#406!H2F
M*J8F&A.&?DT*0Y%586@HSL(/PR=73VLX% :_)2K\           @$N(+ T)=
M?*HZFA-AV(B$H3XW#3\ _UP]I>%$& )6*6!E)        $ Z2$(8#'>=(;#J
M,A*&GVT4AOJ\:WAIH;A^01N\3<E:&':[RD/]8-<%        0%I(11@,=Z]-
MBJ^.'LQ0&!8^$(;SFY65>7A182F^K0OQ4M 1AH,/"\/^A8H[B;Q/T08
M    IDA(& QWYT#7RC+65$09A6$P?6&H3 _2:R5QZ;]>9[@5K0O:K*0I#/Y+
M% E!6K@,"0       ) FTA(&(SI93OV-#551OS8I#/FA2ZO2 [6*&KR$V"!M
MR$O5Q9U4!VY4FA6&PRL4D0'JVPF@"@       ("DD:(P&*&T,E79Y?I;/M57
MEU9<FO&7,$PIO;2HXLK6VHQ 1=EU7C=RYHJ&*JKXCCXW39>;JLM)U15GZ>LJ
B*/Q.         "!)_A^6L1,=D>"BX@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm139718175489840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Mar. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 22,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Humacyte, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1763759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2525 East North Carolina Highway 54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham,<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">313-9633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUMAW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "].'98&445]3<!   G @  #P
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M%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "].'9899!YDAD!  #/ P  $P
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ O3AV6)E<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " "].'98BE=^>A0%  !R%@  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ O3AV6)^@&_"Q @
MX@P   T              ( !6 T  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" "].'98EXJ[',     3 @  "P              @ $T$   7W)E;',O+G)E
M;'-02P$"% ,4    " "].'98&445]3<!   G @  #P              @ $=
M$0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ O3AV6"0>FZ*M    ^ $
M !H              ( !@1(  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ O3AV6&60>9(9 0  SP,  !,              ( !9A,
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  L!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="huma-20240322.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humacyte.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="huma-20240322.htm">huma-20240322.htm</File>
    <File>huma-20240322.xsd</File>
    <File>huma-20240322_def.xml</File>
    <File>huma-20240322_lab.xml</File>
    <File>huma-20240322_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "huma-20240322.htm": {
   "nsprefix": "huma",
   "nsuri": "http://www.humacyte.com/20240322",
   "dts": {
    "inline": {
     "local": [
      "huma-20240322.htm"
     ]
    },
    "schema": {
     "local": [
      "huma-20240322.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "huma-20240322_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "huma-20240322_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "huma-20240322_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 27
   },
   "report": {
    "R1": {
     "role": "http://www.humacyte.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240322.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "huma-20240322.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, par value $0.0001 per share",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50",
        "label": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.humacyte.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001818382-24-000034-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001818382-24-000034-xbrl.zip
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MG"QZ)> ;P 2)<E("7VX9V?F:$3_.D!BX3$<)]=&7;UD$2#^;H*(P?YP!9)P
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ML:6=KIZ3C'']'C+^*D4U,;]_E&>]1*V"JHL%.!%J0TBE\#IQ%DDQZ<3^LC^
M^TN83),L$?$]CC-W!&K@L;"0CJA@C^I)Z?^8%/[ 0P:=^Z A<VJI;1G;<)LU
M]^&NS(].KELZ[N79:$\QY3+MZA 5U@R[?NC6:\TGB;=ML09]_/TMN2+A@9)+
M$@L20VPCR+\AM$E]KH,S",@P3< 7Y5AU%7<TXO]1S^^_!5?MD!ZXQ\-3W'X@
M*%U$L\A;P[)G7ILW)ND.DS">,*&6>5DT"A%?W[EP7H]SX;AFM5K;BD>PQ:&J
M3;-AK^5*+O/CX3K\&++@ 3UGFGP/\\N;*OI3WQ<L3?/_/L)X]E3)-TIMI^;4
M2)>FDES$0@Y(APIPJ"-*?H<I1W1":L\D&]90 LO^^(M,A:J#VH7.V(ZQS8G?
M@9^7XC8>S1RZ)CATF1C087F[#DH14^^.7)LFS9:(IHSRI;@"9YBK6J@\;6V5
MVA>=GVY=,=&N8H@@PO_CB0XO<I+9(._UNNUN[L^MI4GWSK+GQ,"T3"* >7A"
M0\+&S,LDO\=L#1AXEKXU?P96'5#PV4O=E:>RE\_LE>V+C3Q87VQ0)Y\*1I<$
MQ2FUF_:#L.?]IGKL8PP,<36(HY7 U'9+;==VC>:A^[@L[IZVC^0[YXG=O__:
M<.SZ44HD"UF">))((5HF(&UAAB)#*!!WA1]WGSM?CXTN8DE.$ZR:0K%Y06W-
M3M;G0RR E?*$M%"I)7BD6A?"R@1$;]2!)XT&E83H_>D=KK67:$>X=0;,^Z**
MYFF2B!B4.@;L_7A,^BR,1X@;-B(%2,/X@P0\1!;D*?"C9)$/.,L8T!YFH:01
MB[,TG) 48KPTF*@O\P_B/JQC'N+K(1?2^AF, _2,)M.V (*W>(3?8<:.8[R<
MMC:@Y%Y%AH_%9HYIU9VM1'/-0_/0:7RC5/%7.[Z?86 <//TZ*[R^D?@LN 3>
MQ%Q+%N4)A_39ZF^[6FK';R-F*"9@3A; 89$N)%FHF[C.0&RJ$+]JB5RI1\ R
MA .[3CH?KHGC6B9T+/"(?A FNXE5Z2],>0X:$]1F^#R'U=XXA\UI0H8Y41ZR
MEUVEX XN<-A2F<N,OZJ@N53/'Y?%K@1#'89G0%2)&9I;<1D$Z/8^QVJ';YS5
M@#:&MT"<9[6:7?4-YZ#_?CW&TWU_LEY.W5Z:9DQLQ(#UGPRXPH N,ZH'WGH,
MF/?]BH3#OGG!;ZBH91=QVH(;I@,G)B#T6F0R6VFW/( "AMK?>*G9-!O5QL95
M.K;9>";(6?]]U3K<3I'.O@+E/AU9OJG*H5L\MZQKC+T!\? 0WP:69J8&W@0I
M!%4IPIO)L!^'!QMEXM\4(2[RXE'%$FQJ9^.(C ;<&ZB<^UR/;N+FY=I1*<]B
MN[)7.QHOV -SEL)<;7<FMM-78C;S[QJEMCZP3-1QV3))J"#W-,P8^9MR!&R2
MX(G>P==5UCW#E#_8:N3BK:5[MA3-4OOW3^>G/ZF\99Z?NN>ZVGZUH!25RG(M
MJ6.! @;GZX*F/OU+RP4YI^(+D^3CQZ=WUI_3.M3[<B=B"!V,G%Z>QU@0O)D%
M<-=1.HY=:E\SG[&A\E?S0_EI66OYT2"&ER/]$C>EA<=3U3' JL*(:66$5F%1
M<Q$J"1 C[\]P7]M3G?YFVV;->H%4/;M8SXG;#[78A3K-<;1.^_R3_-])UC96
M=NY7*KL]#[A[D8^Y'$;Z$^*I35* ZPLH&:8JF5=V,'FJ= C@>H?N-[#/2 XP
M)93@KB9-B<\"F$(=6M*;+%9M&JNO[+#H@YXN.<#=\?J1VFB9=N;JN%."QYUP
M(UKGE9R^X12,571Z=#8HYICFWRT,:^[Y?G6WF,3+E03?+:OZHO+1*0J_*0PZ
M&H&BA*H4V=ST54OM\4L/J>Y*A((GA (+6@HEC#\H#QB _+"0>7C'7Q2K9%<&
MAAI[ :'S(@2\'XZK^@)]]XTR^CA7.,')U=V *(L1X 8M@MV#L8=>/**1AQM5
MU//P_!!VQCOB?"K\5)<?^"N9MOGI\@,ZR[@MBIOYJMAQ?#NCG3Y3_?Q%:4]N
M9.Y;NG%_$],K%^1LD)Q>JW9P\2*F)-8KW!(LI%BK^>!JICF("C9K_@GM0\27
MR<<_V:2V<?6VI_4NFZK/+IL:B'GP>L>,OF#TBT$#F+1%PQ&=I$BT;WHCU7?3
MJL4E=#W)AL0Q+<<DURS-0JFJ<2]!Z^4[3Z"[R(>96NO$H&:Q8;-:05#.L)(M
M]W!GUN,R(LM7-)3)\CEW<+K2#%0S!2V--<G V8RFRG* [E95:D";N8(7.;70
M,.B6%-0&/&9X3..O3!TC5]0+LC D>&,$T<;EC'GZ\CC75J"X)CD%Z4XF,_=I
M&0)X$60BXND P4-7;,#[7))FT[31@*A/.ID0N&^87Y2!)\*F178(P_Q8'(P!
M'B<#SQ$,Y>Q6R+4=M7U93PP6>#2[PE49)JI\8HW=8H6K-NV::%1*B.[S;C(N
M8Q0/RX..0)\13 9 &];-.@ ]#YFO?MM':IW!;(,:8TI$9F:[L::W7,:UHT/-
M P?X03[-8N=\MO=E]"J6%FUQM=#O1^\CKX9\M+PJ=_X79U8#KWH89<QILT3?
MB*#HT4>**3;$ DP(P@)U^@B R&],\):A23,0+9H#5,!,:UX":!7= H@AHP%<
M)Z@G6VDV!(Z<'.V1]FR:EFTNZ,C9!9!:>>;BFNZY>XV7&DU!W21L>Q7>EUTW
MF\VGO:_UW]=J]:ULK-:!<6I/W^[P+8J$9E[*]\XBY=SU@+=V='8@TY>OOO2L
MY%969*>;FF<L]01/EKRYK]D\6-S7,6M+.SO/;.[LE%F+U2$Z5VLSQS?+$7]O
MD@;!-ZMQT\#YS,OO9F@IKP5[ 4RTT-;G/MO1S@$D!9>KC]EXW&S:YD .5?G>
MW&$O$U]Y;,OQ!MA46G0TNSCJMZM/A?T/V"50_U[.;M_J^V^P#[E?=9NV5=W3
M/:0B.@VY[X=L5V?#8H"&7%$(.7J8U0$)QT.^9U12?7O) 4;%OI__Z14(*C!,
MZ2F'D:@_T>+G=S4N;"L\O__SW=)6A6'*OAPZ7+5E+TJ;X;'8O<N;[<UAU)O>
M;Q>GMY^NNZ\ME;)XU:W>*_DKXR*/8-?-;11LLOA9."$>S7!C1.6H]!E6G*8/
M$2,L&#3$^MK%/AO0,,#\ @ZD+&_> ?,T603?J.%H)@>Q .3\-Q>CUBRS;F]6
M_/MHR:YI5[=S%K1J-JSF=F Z-)ONTZ'VFM%NH;%L[O.9C^+X"RM2.O^Z[99)
M[Z)38-(V<PHW#% +NSV\160+5P/M87"'=SRW5OSSC3,!>\1?Q;[I/R>M1WW3
M%]^\M3MT]"YX):V RPC:_-0D-Q3MQ$M.U7V-D!07LFXK.M\%9;%(ZW%6>7OX
M[@O_O!J"J;+9=3CDU6#4&7 6+.S97*JKID29Z(;.=-^-G+%[%L:).I.9=U*[
M.K<0\:29*&*?W8>B^Q)U.H]'G17]!R'57Y%L_Q=02P,$%     @ O3AV6!<K
MSA62 @  _0@  !$   !H=6UA+3(P,C0P,S(R+GAS9-U56V_3,!1^[Z\P><;-
MM915:R>Q"0FIP#0VL3?D.B>)M<0.MK-V_Q[;K=6F*VR1>$#D)<XYWW?NQSF_
MV#0U>@2IF.#S(!Y' 0).1<YX.0_N;C_B]\'%8C0Z?X/Q_8>;);H2M&N :W0I
M@6C(T9KI"ND*T'<A']@C0=<UT860#<8+1[L4[9-D9:51$B69AWFMG&492;.8
MYC@E48$S0M]A0B8Y3K+5%%*:Q?&$OBUG-,EHE$U6>)+&4VQT!!,#P?%T D4\
MS=)T.G5&-VJF: 4-028UKF8;-0\JK=M9&*[7Z_$Z'0M9ADD4Q>']Y^4W!PUV
MV)KQAQYZLY*UQZ>A5:^( @^ONH;TX%9 GS2,J6A"FVZ4)DF B-:2K3H-'TU=
MKJ @7:WG0<=_=J1F!8/<%+T&6]8>X$"MB2Q!?R$-J)90>(73Q0@A6PO6M$)J
MQ)]1"Z)6+K5.X9*0UE+3 &UKMQ24:#<2%JT,W%7B)">$6BLOP58RWJ@\"%^,
MX* =\=G96;BQ]3T=P<EV.#RV1QPG.(T'N.T;8EQIPBD,\6V^L.?]C1CVLS4L
M!L\;'H,SIH".2_$8YL!>,P#'<'LXT7+"N=".;R4[6=LR7HBMP(ALX#,?_0T4
M?EV?[>")$7&O&9%4BOJ%>0I;*5J0FH$ZW%]GH))0&+;9'^SWYD<K86PB\9!G
M#OHML&KC 93979?O<I^0-Z&?6F-"F3[4L"W1OYQ_#L70_ V%<?9?9%^3U=#L
M#07J@8E;XJW1(Y;/@TMA_K_7I#2!6?G=S:??7^_.XY[@K7J[^TXL(O?$".]_
MV1@Y)K+4\_"8<&2J4Y!_Y0MW/A[P'7D'^0.1DIIV]7!>?Z).TG9"7\G=/1/V
M+YKM]\%EY 3;&VXQ^@502P,$%     @ O3AV6!]6]D"""    SX  !4   !H
M=6UA+3(P,C0P,S(R7V1E9BYX;6S=6]MNVT@2?<]7:+VOVQ;[WFTD&62=9&%,
M,C%B#S+8%Z$O18D(11HD%=M_OT5*BB]2G$1D9B&]V!39[#I=I[KJL"@]_^UF
MGH^^0%5G9?'BB!XG1R,H0AFS8OKBZ,_+M\0<_?;RV;/G_R#DKW]_?#=Z78;%
M'(IF=%J!:R".KK-F-FIF,/I45I^S+VYTGKLF+:LY(2^[VT[+J]LJF\Z:$4N8
M6 ];7ZU.A'!<T! )=TE*A N*."<C8<)KX$%0*L._IB>!B9 (Z8GD5!.\YHC#
M(81J"2G5@G.MNTGSK/A\TO[QKH81+J^HNX\OCF9-<W4R'E]?7Q_?^"H_+JOI
MF"4)'Z]''ZV&WVR,O^;=:&JM'7=7OPZMLVT#<5HZ_NO]NXLP@[DC65$WK@AW
M!M!\;+[>>!^-'"\OXM Z.ZF[^]^5P34=0=]=PNB;(]I/9#V,M*<(9833XYLZ
M'KU\-AHM/>>J4)4Y?(1TM#K\\^/9)M*L:,8QFX]78\8NSQ%Q-T-S>P4OCNIL
M?I7#^MRL@O2;Z-=+;D')%LX_V]G&O3'-$$@5%AX(GH6B#?$!,6Z;O3_FKW.1
M"*E;Y,V B#?G'A1O.7?9D [>F'H M-U$9 YS#]604!_,>P_G&N1CA.V4L\7<
MA=L&CD,Y'W?P3DO,Q.=N"C\ #6\F;4)-.&,=AKN;[]E'HK,B:W/'._RXFJ&U
MM1L2N&F@B+#,%VL;>1D>#,K;;%5^=6_N/.3=V4F$;/*F:++F]JQH2X1; 8.S
M!N;U)*0R>"8LX2P $2)2XB4'0KFVQD7E$D$W":K7A-<0CJ?EES%:0988;P]:
M%_$E14_:7OJLQXHRJ"^=SV'B@V4ZC9XD,A%$X$8C)E!'0)J0T"2&R+9$V<\N
M8FWN(>X[ME]5ZQ6L0O^G,GA:E?/!&6O*(5RV) 0Q'XW**D*%F@4O==OQ).1E
M#?'%45,MX.YD6308MF]R:&4+;B:8M@>[$KZHR=2YJ\E%@^JGG>@T=W7](;UH
MRO#YU4U63QCG/!&M,E$"]0RWJ&? &!*E,*EQG@9AGPB U-6^XV=E:1D%D#?U
M^LQ=.'P7S(#A\40QW1(NNW%;_@H?;XN8GN3?Q_.Z2_T_A&CRJ*0/Q/XFF@%I
M_Z8>N2-]8+K*7^+KOR<**#ZA)!H4832Q1!CCB&>HL@U(RBESSHJXI^P_4'?_
M1_)_QL6_@O1R/B^+#M#[3NU-3+1IH D0G8+#&JBP!G(E2'":>A.59-8/S?EC
M$$-2ODTB;_+=EYG'1/=RZR;/25^>/[FJ<D6S!N."5, 4T0+#5R@'Q&H>273&
M66F4%LG0^_H!@+WG=W=W#KB'6W6R[E]=XMA)8KGW1FB2IA)QM$<F31E)A/,^
MX!45GI)JW]?J]ZW]?1S^(M&^L^L&W)[W<9Q#E97Q31%?8^G!58&$Q%DBA<7H
MM"829WA"0JJ,L3XHZY_:HC_.Y0.S!T/J[LX<>(,NU_@1IEG=M"GC#S>'B75<
M,>""I)HA'HDAYR1CQ'IE(- 0K)<#= 8>6MU[;GN[<I-:UI_:LR*4U559=8OL
M9.-IN2B:ZO:TC B/44V-$$0GH#'R9$IL3 S1 )A8J.4!U" ]H"= ' CQPSEZ
M,PYX_SAXF^7PQZ+3 ](:'3D:1WV!,0DRM.'HB?96X*.":-_\#$#ZG<4#87A'
M%V[2*?K3>>ENSB(6DBS-EB^K5L!P+/@$&%&J%0HT!5RA8IAY$*0S46O.!N#V
M&^8/A.@AG+O)NNS/^JL8*ZCKU;]VN702F:&>>HX/!ERV2Q4H#;W$S))02%-/
MP0S0 =]F^D#8[NO43:;58$R?XN&'ZK*\+B;:6*,\%20F"BN(HIHXS3W6DM18
M8"FN=(B=O6'XL%C>T:&;'.O!..ZTPH?JO"J_9$6 ":#DAU1'?,SSF%L\>.)
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M+<A^G8X'YO:>SMV=MX7&5=?J^?B1-Q#FYY?/5J?;/^T/@5\^^Q]02P,$%
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MAL"+Z2,E<5Y?7CV[.]%]=/\*_^K9_P!02P,$%     @ O3AV6.J;2+Y?)P
MJYP! !@   !H=6UA+3(P,C0P,S(R>&5X>#DY,2YH=&WM7>MSVT:2_WY_Q9R]
ME[7K0 8/OB0EJ5(D>YT]._;93E+[:6L(#,6)0(#!0S+OK[_NGL&#%$F1$D6
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M;MFVXZKB">I-^$0.-6W@79S]F=Z(0/H"I@^OR=]1'@F6)?PV0YT"I$,**LZ
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M;5].#&R;4Z(%!= IVBZC.,G[N[CP&NGIP]BZ6\*=7K$/;[F;M8\A6N;-&/#
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MG&P+E!HN[9M+MC$85+B7=N3HUBFYOYS07\.$NO(MQG4>8V8U+1X1J*^A0/;
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M+FAT;5!+ 0(4 Q0    ( +TX=E@7*\X5D@(  /T(   1              "
M 780  !H=6UA+3(P,C0P,S(R+GAS9%!+ 0(4 Q0    ( +TX=E@?5O9 @@@
M  ,^   5              "  3<3  !H=6UA+3(P,C0P,S(R7V1E9BYX;6Q0
M2P$"% ,4    " "].'98P=,%A_4,   (;0  %0              @ 'L&P
M:'5M82TR,#(T,#,R,E]L86(N>&UL4$L! A0#%     @ O3AV6*\W(K0U"
MVD   !4              ( !%"D  &AU;6$M,C R-# S,C)?<')E+GAM;%!+
M 0(4 Q0    ( +TX=ECJFTB^7R<  *N< 0 8              "  7PQ  !H
M=6UA+3(P,C0P,S(R>&5X>#DY,2YH=&U02P4&      8 !@"- 0  $5D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>huma-20240322_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="huma-20240322.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818382</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-22</startDate>
            <endDate>2024-03-22</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0001818382</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-27">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-03-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityRegistrantName contextRef="c-1" id="f-4">Humacyte, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-5">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-39532</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-7">85-1763759</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-8">2525 East North Carolina Highway 54</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Durham,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">27713</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">313-9633</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-18">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-19">HUMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-21">Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-22">HUMAW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-24">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-25">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
